Actuate Therapeutics (ACTU) said Tuesday that its phase 2 trial of elraglusib with gemcitabine/nab-paclitaxel, or GnP, in metastatic pancreatic cancer met primary endpoints of one-year survival rate.
The study demonstrated a one-year survival rate of 43.6% in the elraglusib-GnP arm compared to 22.5% in the GnP control arm. Median overall survival was 9.3 months for the elraglusib combination versus 7.2 months for GnP alone, Actuate said.
Actuate said it plans to share topline data and discuss next steps, including a phase 3 registration trial, with the US Food and Drug Administration in H1 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。